[Antisense inhibition of cyclooxygenase-2 reduces malignant phenotype of gastric cancer cells].
Hanping Wu, Kaichun Wu, Liping Yao, Meihong Xu, Daiming Fan
Abstract
Hanping Wu, Kaichun Wu, Liping Yao, Meihong Xu, Daiming Fan
Abstract
OBJECTIVE: To investigate the role of cyclooxygenase-2 (COX-2) in tumorigenesis of gastric cancer, and the introduction of into human gastric cancer cells to suppress COX-2 expression. METHODS: The high COX-2 expressing human gastric cancer cell line SGC 7901 was stably transfected with the COX-2 antisense recombinant vector and plain vector (named as 7901-AS and 7901-P cells). The COX-2 expression levels in transfected cells were detected by immunocytochemistry and dot blotting methods. Proliferation and tumorigenic ability of transfected (7901-AS, 7901-P) and control (SGC 7901) cells were evaluated in vitro with MTT assay and in vivo with nude mice. RESULTS: Antisense treatment for COX-2 gene significantly reduced the expression level of COX-2 protein and mRNA and led inhibition of proliferation in 7901-AS cells. The tumor graft of 7901-AS in nude mice 30 days after implantation had less volume and weight than that of SGC7901 and 7901-P [(486.67 +/- 15.28) mg vs (826.67 +/- 77.67) mg and (776.67 +/- 300.06) mg, P < 0.01]. CONCLUSIONS: Overexpression of COX-2 in human gastric cancer cell line SGC 7901 was related to the malignant phenotype of cancer cells. Inhibition of COX-2 expression by antisense technique could reverse malignant phenotypes of gastric cancer cells.
OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE: To investigate the role of cyclooxygenase-2 (COX-2) in tumorigenesis of gastric cancer, and the introduction of into human gastric cancer cells to suppress COX-2 expression. METHODS: The high COX-2 expressing human gastric cancer cell line SGC 7901 was stably transfected with the COX-2 antisense recombinant vector and plain vector (named as 7901-AS and 7901-P cells). The COX-2 expression levels in transfected cells were detected by immunocytochemistry and dot blotting methods. Proliferation and tumorigenic ability of transfected (7901-AS, 7901-P) and control (SGC 7901) cells were evaluated in vitro with MTT assay and in vivo with nude mice. RESULTS: Antisense treatment for COX-2 gene significantly reduced the expression level of COX-2 protein and mRNA and led inhibition of proliferation in 7901-AS cells. The tumor graft of 7901-AS in nude mice 30 days after implantation had less volume and weight than that of SGC7901 and 7901-P [(486.67 +/- 15.28) mg vs (826.67 +/- 77.67) mg and (776.67 +/- 300.06) mg, P < 0.01]. CONCLUSIONS: Overexpression of COX-2 in human gastric cancer cell line SGC 7901 was related to the malignant phenotype of cancer cells. Inhibition of COX-2 expression by antisense technique could reverse malignant phenotypes of gastric cancer cells.
Key concepts: Transfection, Carcinogenesis, Cancer, Cancer cell, Cell culture, Medicine, Molecular biology, Immunocytochemistry